The race to market the EU’s first beta-amyloid targeting antibody therapy for Alzheimer’s disease between Lilly and Eiasi could be heating up as the former’s donanemab will likely be among the drugs that are this week discussed at the European Mecicines Agency with respect to whether they should be recommended for pan-EU approval.
EU Marketing Approval Gap Between Lilly’s Donamemab and Eisai’s Leqembi Could Narrow
The European Medicines Agency is this week set to issue an opinion on whether pan-EU marketing should be granted to Lilly’s Alzheimer’s disease drug donanemab.
More from Europe
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.
• By
Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.
• By
The new global GCP guideline, ICH E6(R3), enables researchers and clinical trial administrators to tailor their documentation processes, but also opens the door for more scrutiny during GCP inspections.
• By
A German ordinance implementing the EU Health Technology Assessment Regulation offers little clarity on how far joint clinical assessment reports should be considered by national authorities.